Figure 3.
Figure 3. Inhibition of tumor growth in mice immunized with DCs transfected with VEGF, VEGFR-2, and Tie2 mRNA. (A) B16/F10.9 melanoma model: mice were immunized with 5 × 105 mRNA-transfected DCs 3 times at 7-day intervals and challenged intravenously with 5 × 104 B16/F10.9 tumor cells 8 days after immunization. Mice were killed based on the metastatic death in the control group (25-35 days after challenge with F10.9 cells). Metastatic loads were determined by measuring lung weights. Columns represent mean lung weight and circles represent individual lung weight (5 mice per group). (B) MBT-2 bladder tumor model: mice were immunized with 5 × 105 mRNA-transfected DCs for a total of 3 times at 7-day intervals and challenged subcutaneously with 5 × 105 MBT-2 cells 8 days after immunization. Day-18 measurements are shown. Columns represent mean tumor diameter and circles represent individual tumor diameter (5 mice per group).

Inhibition of tumor growth in mice immunized with DCs transfected with VEGF, VEGFR-2, and Tie2 mRNA. (A) B16/F10.9 melanoma model: mice were immunized with 5 × 105 mRNA-transfected DCs 3 times at 7-day intervals and challenged intravenously with 5 × 104 B16/F10.9 tumor cells 8 days after immunization. Mice were killed based on the metastatic death in the control group (25-35 days after challenge with F10.9 cells). Metastatic loads were determined by measuring lung weights. Columns represent mean lung weight and circles represent individual lung weight (5 mice per group). (B) MBT-2 bladder tumor model: mice were immunized with 5 × 105 mRNA-transfected DCs for a total of 3 times at 7-day intervals and challenged subcutaneously with 5 × 105 MBT-2 cells 8 days after immunization. Day-18 measurements are shown. Columns represent mean tumor diameter and circles represent individual tumor diameter (5 mice per group).

Close Modal

or Create an Account

Close Modal
Close Modal